ADVERTISEMENT

Bacteremic pneumococcal pneumonia: macrolides vs quinolones

Liz Scherer   |   Clinical Summary   |   28 December 2022
ADVERTISEMENT

Macrolides provide survival benefit in bacteremic pneumococcal pneumonia

Takeaway

  • Macrolide empirical therapy administered reduces mortality risk by as much as 45% in hospitalised patients with culture-confirmed bacteremic pneumococcal pneumonia (BPP).

Why this matters

  • Consider azithromycin or roxithromycin in combination with β-lactam therapy to...

          

Topic Challenges

left
right